|
| Terms used | Predominant manifestation/location of symptoms | Supposed underlying pathomechanism |
|
| Syndrome de Widal | Airways | Pathomechanism unknown, hyperreactivity/-sensitivity to aspirin and aspirin-like drugs |
| Samter’s triad | Airways | Pathomechanism suspected to altered sensitivity of chemoreceptor, hyperreactivity of airway mucosa to aspirin and aspirin-like drugs |
| Aspirin idiosyncrasy | Anywhere, ubiquitous | “Peculiarity” of hypersensitive reaction to aspirin and aspirin-like drugs which is not elicit by immunoglobulin-mediated/immunologic reactions, but by dysfunction or loss of function of enzymes |
| Aspirin allergy | Anywhere, Ubiquitous | Involvement of immunoglobulin-mediated/immunological reactions directed to aspirin and aspirin-like drugs |
| Pseudoallergic reaction to aspirin | Anywhere, ubiquitous | Reaction to aspirin and aspirin-like drugs, causing symptoms as seen by allergic, reactions (i.e., immunoglobulin-mediated/immunologic), but without involvement of immunological reactions |
| Aspirin intolerance | Anywhere, ubiquitous | Pathomechanism unknown/not defined, but aspirin and aspirin-like drugs are not tolerated by an individual |
| Aspirin sensitivity | Anywhere, ubiquitous | Pathomechanism unknown, but hyperreactivity/-sensitivity to aspirin and aspirin-like drugs, symptomatic description |
| Aspirin-sensitive asthma | Lower airways | Hyper-reactivity to aspirin and aspirin-like drugs causing airway obstruction |
| Aspirin-induced asthma | Lower airways | Pathomechanism unknown, but initiated/induced by aspirin and aspirin-like drugs |
| Aspirin-exacerbated respiratory disease (AERD) | Airways, systemic | Exacerbated by NSAIDs blocking COX-1 pathway |
| NSAID-induced rhinitis and asthma (NIRA) | Airways | Exacerbated by NSAIDs blocking COX-1 pathway |
| NSAID-induced urticaria/angioedema (NIUA) | Skin, systemic | Exacerbated by NSAIDs blocking COX-1 pathway |
| Single drug-induced urticaria/angioedema (SDUA) | Skin | Exacerbated by a single NSAID blocking COX-1 pathway |
| Multi-drug-induced urticaria/angioedema (MDUA) | Skin | Exacerbated by multiple NSAIDs blocking COX-1 pathway |
| Single drug-induced anaphylaxis (SDA) | Systemic | Sensitisation to a single NSAID blocking COX pathway, suggested immunoglobulin-mediated/immunologic pathomechanism |
| NSAID-blended reaction (NBR) | Airways, skin | Pathomechanism unknown; not AERD, not NIRA, presumably not immunoglobulin-mediated/immunologic |
|
